Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Patient-reported outcomes can be critically important, said Justin Bachmann, MD, MPH, FACC, instructor of Medicine and Health Policy at Vanderbilt University Medical Center.
Transcript
What is the importance of patient-reported outcomes in cardiology and how can they be better incorporated into payment models?
I think, I’m a little bit biased because a do a little research in this area, but I think patient-reported outcomes are critically important certainly to cardiologists and medicine at large. Patient-reported outcomes focus on what is important to patients, outcomes that matter to patients, what is the patient’s quality of life, how are they feeling, how functional are patients, how much time can they spend with their families. These are things that are critically important above and beyond traditional outcomes such as mortality and readmissions.
We have some very good ones in cardiology. We have PROMs, patient-reported outcome measures, that have been developed by John Spertus, MD, MPH, who is really one of the fathers of patient-reported outcome measures from Kansas City. John developed the Kansas City Cardiomyopathy Questionnaire and the Seattle Angina Questionnaire. These are questionnaires that are highly predictive of mortality and readmissions and also measure quality of life. These are measures that very easily integrated into any kind of value-measured program.
Other PROMs are being developed to focus on conditions such as atrial fibrillation and you start combining those with more general measures of quality of life and NIH [National Institutes of Health] is are developing some of these. They’re called the PROMIS measures. You really have the underpinnings of a very robust measuring system.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More